American Well Corporation (AMWL) Options

Been holding above a buck pretty well.

AMWL: Just posted same over on Orion's. (Where YOU don't post anymore; and where they all IGNORE my posts anyway.)

U.S. Defense Health Agency selects Amwell® and Leidos to power the Digital First initiative for the U.S. Military Health System
October 19, 2023 at 04:26 pm EDT
Share
The Amwell Converge™ platform will enable DHA healthcare teams to deliver connected and seamless in-person, virtual, and automated care delivery for the Military Health System

Amwell® (NYSE: AMWL), a leader in hybrid healthcare enablement, together with Leidos (NYSE: LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a next-generation contract to provide a hybrid care technology platform designed to power the “Digital First” transformation of the Military Health System (MHS).

Under this task order, the Leidos Partnership for Defense Health (LPDH) will deliver Amwell Converge™, a comprehensive hybrid care enablement platform designed to power the full continuum of care using digital, virtual and automated modalities, and replace the Military Health System (MHS) Video Connect solution. It will start at five initial sites followed by a phased enterprise roll-out. Also included in the contract are a broad spectrum of Amwell automated care programs that have a proven track record of helping deliver better health outcomes, including multiple behavioral health and integrated core telehealth solutions. If all options are exercised, the task order has a 22-month period of performance with a total value of up to $180 million to the LPDH.

“Through our world class platform Converge, Amwell is already enabling hybrid care across the commercial marketplace. With this agreement, we are pleased to offer our unique capabilities and help improve access to quality care for the MHS community of users. We are grateful for their service, and honored to have been chosen to join Leidos in supporting the Department of Defense as it seeks to adopt and extend the benefits of hybrid care to the Military Health System,” said Ido Schoenberg, M.D., chairman and CEO of Amwell.

The DHA’s Digital First initiative brings new capabilities and enablement to MHS GENESIS, an advanced electronic health record (EHR) and healthcare system solution that supports military and Veteran healthcare initiatives. The Converge platform has deep integration assets and a simple yet powerful user experience that enables efficient and quality hybrid care delivery. The platform is already embedded into existing clinical workflows that care teams rely on, including those within the core EHR that powers MHS GENESIS. Together, Amwell and LPDH will enable the DHA to leverage the benefits of hybrid care, improve access to primary and behavioral health care, and ultimately improve outcomes for the MHS community.

The DHA supports national security and ensures our nation’s military teams are ready to deploy. Seeking to leverage innovation and best practices from the commercial sector, the DHA conducted a thorough evaluation of the Amwell solution.

“We are delighted that the demonstrated scalability, flexibility, and comprehensiveness of the Amwell Converge platform, as evaluated by DHA, uniquely qualifies Amwell to support the DHA’s Digital First strategies and readiness mission. We are dedicated to supporting this program with the best that Amwell offers for many years to come,” said Dr. Schoenberg.

“Digital First addresses DHA’s goal of better outcomes, new processes, innovation and increased standardization based on evidence,” said Jason McCarthy, Leidos senior vice president, Military and Veterans Health Solutions. “As part of our overall MHS GENESIS effort to enhance patient experience, we, along with Amwell, are looking forward to providing near real-time, self-service support and hybrid care options for our customer and those whom they serve.”

Digital First will support the entire MHS community of users, which includes 9.6 million active-duty service members, family members, retirees, and health professionals across the continuum of care. Through integrated platform solutions, Amwell and Leidos will help reduce burdens on care teams, improve the mental health and wellness of beneficiaries, help reduce healthcare costs and optimize the effective utilization of DHA's clinical resources across their global enterprise.

About Amwell

Amwell provides a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. The company offers a single, comprehensive platform designed to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the hybrid care of more than 55 health plans, which collectively represent more than 90 million covered lives, and many of the nation’s largest health systems, representing over 2,000 hospitals, have access to Amwell solutions. For more information, please visit https://business.amwell.com/.

©2023 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.

This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations, financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions.

Anyone still monitoring this? Been getting hammered, seems like a good entry point.

TELADOC COULD BUY AMERICAN WELL
NO MORE

HOT STOCK PICK:
If you know your charts - take a look - a no brainer to head upwards and rake in dollars.
Strong Buy!

Breaking News Alert: Raised to BUY from Neutral - and Target Price announced at $15 by Guggenheim. To the roof she's heading.

Yikes didn’t last long. Terrible

Sold my shares from $21 to $41 in 3 months. I like Amwell long term but will look for a better re-entry. Good luck longs!

Maybe not

Yea looking strong

Beautiful at $33 today.

Today is $32.××.
Within two more weeks, Amal will be in $40 range.

OUTSTANDING!
The rest of stock markets are red , while amwl is green.
With amwl , we are not talking about penny. We are talking about $1 ,$2, $3, for upside.

If amwl can advance upside $7 every month then in one year, pps would be greater than $100.

Example
Tdoc did ipo back 2015 at around $30. Now tdoc is trading at $197

If amwl can advance upside $7 every month then in one year, pps would be greater than $100

I tracked the movements in one month..
Downsize minus upside = pps had advanced upside about $7 from 21.99 to $ 30.42

November 17, $21.99
Dec 2 (today), $26.xx
Upward movement will continue.

Great job

$40 with good news

Well then

Dow , Nasdaq and s & p 500 are red while amwl is green at 5.52 % higher than tdoc. So I think it is a good sign for good earning.

Amwl and tdoc are competitors to each other on main street , but on stock, they are allies.
When all tdoc or docrf are up high , amwl will be high also.

Earnings today.
Let’s see

Up up

a few dollars more

I expect it will reach above $35 by Tuesday next week.

I had been watching and preparing to buy at below $25. But it didn't drop below $25.
Anyway I am happy that bought at $25.35.
Today it's closed at above $29.
Not bad

Shorts?

Looking strong, liking the green bounce. Think we’re headed to $50+ or more by hear end

Think we may get a short squeeze here. Got some calls going....

Oct - Dec is a very busy telehealth month, and with the possibility of a second wave, the squeeze could be epic.


$AMWL

This is riding on TDOC coattails...nice ride!!

She got it

She wants $40

$35 and climbing.

Weeeeeee

Yep, looking better and better each day

Amwell Expands Partnership with Tyto Care to Extend Healthcare at Home

9:00 AM ET 9/30/20 | Dow Jones

Collaboration Will Allow Care Providers on Amwell Platform to Remotely Examine Patients Using Streaming Information from Tyto Devices, Extending the Scope of Care Rendered at Home.

BOSTON, Sept. 30, 2020 /PRNewswire/ -- Amwell(R) (NYSE: AMWL), a national telehealth leader, today announced it is expanding its partnership with Tyto Care, the healthcare industry's first all-in-one modular device and examination platform for AI-powered, on-demand, remote medical exams. Together the companies will introduce exclusive integrations and newly designed workflows and tools to enhance the ability for providers using the Amwell platform to examine and diagnose patients virtually. Additionally, Amwell will become a reseller of Tyto Care's integrated devices.

By pairing the TytoHome handheld examination device -- which enables on-demand examinations of the heart, lungs, abdomen, skin, throat, ears, heart rate, and body temperature -- with Amwell's telehealth platform, providers can guide patients through virtual health examinations and together gain real-time insight into a patient's health data and status directly in the visit. For patients and providers, this will augment the virtual care experience and more broadly enrich the capabilities and overall satisfaction associated with healthcare organizations' virtual care applications. This enriched workflow will be available to thousands of Amwell hospitals, health systems, health plans and employer clients who collectively serve millions of patients.

"As COVID-19 wages on and more patients and providers adopt telehealth, it's critical that we accelerate the depth of care that can be provided in the home -- to keep patients and providers safe," said Roy Schoenberg, President and Co-CEO, Amwell. "Our latest integration with Tyto Care will allow providers to clinically come closer than ever before to patients during telehealth encounters, allowing them to see, interact, examine and deliver care in ways that growingly resemble in-person care."

"Our longstanding partnership with Amwell exemplifies our shared goal of providing deeply integrated telehealth solutions that put health in the hands of consumers, creating a more impactful and seamless healthcare experience for both patients and providers," said Dedi Gilad, CEO and Co-Founder, Tyto Care. "The integration with TytoHome will enable Amwell to offer more holistic care for patients, especially for urgent and primary care needs, as well as help to enable better adherence to treatment plans. We look forward to continuing our work together as we realize the full potential of clinic-quality, at-home care in this new era of telehealth."

One of those IPOs folks a year from now investors will be kicking themselves they didn’t buy for under $100 lol.

30s want to break looking good

Will be half of TDOC price in about 6 months... sooner if any lock downs happen this winter!

AMWL nice jump today after its ipo ~

Going looooooooooong

Yep.

Looking good

Good buy, going long

Thinking this will gain some traction here in weeks/months to come

IPO has Google backing, took a position at $23.50, tight stop.

Telehealth IPO

American Well Corporation is a telehealth company enabling digital delivery of care for the healthcare sector. The Amwell Platform is a digital care delivery solution that equips its health system and health plan, including government, clients with the tools to enable new models of care for their patients and members. Its technology embeds with its clients' existing offerings and clinical workflows, spanning the continuum of care and enabling care delivery across a range of clinical, retail, school and home settings. The Amwell Platform consists of the home line, provider-to-patient telehealth interactions, typically in the home, and the hospital line, supporting provider-to-provider telehealth interactions, or provider-to-patient, typically in an inpatient or ambulatory setting. The Company offers a range of management software, clinical workflows, Carepoint hardware and system integrations to deliver care across various modalities, including video, phone and secure messaging.